1. **Punish countries that undermine international trade pacts: UN Panel – The Economic Times**

A United Nations panel has recommended that punitive measures be taken against countries that use political and commercial pressure to undermine use of international trade agreements.

In a report on access to drugs, the high-level panel has strongly urged the use of flexibility under Trade-Related Aspects of Intellectual Property Rights (TRIPS) which provide for leeway to middle and low-income countries when it comes to imposing intellectual property rights, especially when it comes to medicines.

2. **Centre to open 200 Jan Aushadhi Centres in Karnataka – The Economic Times**

The Centre will sign a MoU with Karnataka on October 2 in Bengaluru to open 200 Jan Aushadhi centres in Karnataka. Union Chemicals and Fertilizer Minister Ananth Kumar announced this to Karnataka Health and Family Welfare Minister Ramesh Kumar when the latter met him at Delhi on Monday. The PM's Jan Aushadhi centres sell drugs at a discount to MRP. These centres will sell 580 generic drugs, according to Anath Kumar. The Centre will open 168 centres at district and taluk hospitals. The government has already opened 32 centres at community health centres, he said.

3. **7 months on, medico-pharma nexus is still alive and kicking – The Times of India**

The Medical Council of India (MCI) in February had framed stringent ethical guidelines to demolish the doctor- pharma nexus that undermines the best interests of a patient. Seven months later though, most feel the rules have had little or no deterring effect. The guidelines mainly elaborate the quantum of punishment for doctors, based on the value of favours or perks received from pharma companies. They state that the doctors found accepting gifts or monetary grants of any kind worth Rs 5,000 to Rs 10,000 would lose registration for three months.
(Online link unavailable at the moment, please refer to the e-paper link)

4. **Lupin caught in legal tussle over 'patent infringement' – Business Standard**

Horizon Pharma, a US-based drug company, has moved court against Mumbai-headquartered Lupin over what it calls 'patent infringement'. Horizon decided to take legal action after Lupin filed an abbreviated new drug application (Anda) for a generic version of Pennsaid, a non-steroidal anti-inflammatory drug.

According to the plea, Lupin should be allowed to market Penn said two per cent only after the drug's patent duration with Horizon expires. Horizon has also asked for monetary benefit, should Lupin be able to sell Penn said two per cent in the US before the patent expires.

5. **Nutraplus mulls entering formulations space, to boost APIs – Business Standard**
Pharma firm Nutraplus India is planning to enter the formulations segment as it also takes steps to strengthen presence in the active pharmaceutical ingredients (APIs). "As a forward integration measure, we look forward to enter into the formulations segment of the pharmaceutical market, which would help us to have greater economies of scale and better margins," Nutraplus India said in a investor presentation. "Instead of targeting high margin branded APIs, we are targeting generic/unbranded APIs which have higher growth potential as countries try to reduce their overall healthcare costs," Nutraplus India said.

6. **Glenmark, Particle Sciences ink deal to develop generic cancer drug Abraxane – Mint**
Glenmark Pharmaceuticals Ltd on Monday said it has entered into an agreement with US-based Particle Sciences Inc. to develop and market a generic version of Celgene Corp.'s Abraxane, used in the treatment of breast and pancreatic cancers. As per the terms of the agreement, Glenmark has obtained exclusive global marketing and distribution rights to the product upon commercialization. "The partnership is a significant development in Glenmark's complex generics strategy and we are pleased to collaborate with Particle Sciences given their strong technical capabilities and understanding of particulate injection products," said Robert Matsuk, president, North America and global API at Glenmark.

Similar reports-
- Glenmark, Particle Sciences to develop generic cancer drug – The Economic Times
- Glenmark inks pact with Lubrizol arm Particle Sciences to develop generic cancer drug – Business Standard
- Glenmark Signs Agreement With Particle Sciences For Generic Cancer Drug – Bloomberg Quint

7. **Working on making plants global cGMP compliant: Sun Pharma – Business Standard**
Drug major Sun Pharmaceutical Industries is working on making its manufacturing facilities compliant with good manufacturing norms and has asked the US health regulator to re-inspect its Halol plant. "We have undertaken a detailed remediation at the Halol facility post the September 2014 inspection. In December 2015, the US FDA issued a warning letter related to this inspection. We have recently requested the US FDA for a reinspection of the facility," Sun Pharmaceutical Industries MD Dilip Shanghvi said in a speech to the company's shareholders at its AGM.

8. **DoP to release mandatory Uniform Code of Pharmaceutical Marketing Practices soon – Pharmabiz.com**
The Union government is now working to release the Uniform Code of Pharmaceutical Marketing Practices (UCPMP) guidelines shortly. The details on the exact time frame were not disclosed. The mandatory code will replace the existing voluntary UCPMP. Indian pharma companies hope to see its early implementation and are upbeat on complying with the new UCPMP.

"UCPMP is in the last leg of clearance with the government. The draft guidance has incorporated suggestions of the pharma industry and other stakeholders," said Sudhanshu Pant, secretary, Department of Pharmaceuticals (DoP).

9. **Indian healthcare segment registers 88 funding deals of $397 mn in 2016 – Pharmabiz.com**
Indian healthcare segment has registered 88 funding deals amounting to $397.41 million during January-September 2016. VCCEdge Indian Healthcare Sector Funding Insights report stated that 54 Angel/seed deals worth $11.19 million, 23 venture capital funding deals worth $155.83 million and 11 private equity deals amounting to $230.39 million so far in 2016. Compared to the

last two years, the sector had garnered $1,342 million and $1, 458 million across 124 and 144 deals in 2014 and 2015.

While the overall numbers for 2016 YTD are down compared to 2015, mirroring funding trends across sectors, the Angel/Seed and Venture capital funding deal values for 2016 YTD are at par and even surpass those of 2014.

10. **NPPA revises ceiling prices of 21 scheduled drugs and retail prices of 21 formulations – Pharmabiz.com**

The National Pharmaceutical Pricing Authority (NPPA) has fixed/revised ceiling prices of 21 scheduled formulations of Schedule-I under Drugs (Prices Control) Amendment Order, 2016 and retail price of 21 formulations under DPCO, 2013 through a Notification/order dated 15.9.2016. Retail price is applicable only to the individual manufacturers/marketeers i.e. who have applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the government under relevant statutes/rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies.